Cobenfy

Boerner

Pharma

As new drugs deliver, BMS explores further efficiency moves

With its $1.5 billion overhaul on track, BMS is "exploring opportunities to further improve productivity and efficiency," CEO Chris Boerner said.

Angus Liu Oct 31, 2024 10:27am

schizophrenia bipolar disorder neuropsychiatry

BMS partner Zai Lab eyes China filing for KarXT after trial win

Oct 29, 2024 1:59pm

scrapheap

BMS' schizophrenia gem Cobenfy was salvaged from the scrapheap

Oct 7, 2024 3:00am